AbbVie (NYSE:ABBV) Stock Price Down 2% - Time to Sell?

Key Points

• AbbVie shares fell about 2% intraday after the company trimmed guidance — Q1 EPS lowered to $2.56–$2.60 (consensus ~3.01) and FY EPS to $13.96–$14.16 (consensus ~14.56), the main near-term bearish catalyst.
• Growth from Skyrizi and Rinvoq is supporting revenue post‑Humira, and analysts remain largely positive (consensus rating: Moderate Buy, average target ~$253) despite some target cuts like Cantor’s $240.
• AbbVie pays a 3.3% dividend yield but has a high payout ratio (~293%) and a stretched valuation (P/E ~88); the stock is trading below its 50‑ and 200‑day moving averages (~$220/$224), signaling near‑term technical weakness.

AbbVie Inc. (NYSE:ABBV - Get Free Report)'s share price traded down 2% on Friday . The stock traded as low as $207.75 and last traded at $208.2170. 4,606,421 shares changed hands during mid-day trading, a decline of 36% from the average session volume of 7,196,347 shares. The stock had previously closed at $212.40.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Skyrizi and Rinvoq continue to drive growth, helping AbbVie edge out Pfizer in recent industry comparisons — this supports revenue resilience after Humira. Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?
• Positive Sentiment: Guggenheim raised its price target to $249 and kept a Buy rating, signaling upside vs. current levels and backing AbbVie’s growth story. Guggenheim Reiterates Buy
• Positive Sentiment: AbbVie sued HHS to narrow the 340B “eligible patient” definition — if successful, this could reduce mandatory discounts and protect sales/margins for on-label prescriptions. AbbVie challenges 'outdated' 340B guidance
• Neutral Sentiment: Dividend coverage and long-term income thesis remain intact: AbbVie is frequently featured in dividend-focused lists (Dividend Aristocrat), supporting income-oriented investor demand. 3 Dividend Aristocrats
• Negative Sentiment: AbbVie trimmed its guidance: Q1 EPS was updated to $2.56–$2.60 (consensus ~3.01) and FY EPS to $13.96–$14.16 (consensus ~14.56) — this is the clearest near-term bearish catalyst and likely a major reason the stock is down.
• Negative Sentiment: Cantor Fitzgerald trimmed its target to $240 (from $250) citing limited near-term pharma catalysts, signaling some analyst caution on how much upside remains. Cantor Fitzgerald Lowers Target

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Cantor Fitzgerald cut their price objective on AbbVie from $250.00 to $240.00 and set an "overweight" rating for the company in a report on Wednesday. Royal Bank Of Canada initiated coverage on AbbVie in a report on Tuesday, February 24th. They set an "outperform" rating and a $260.00 target price for the company. Citigroup reduced their target price on AbbVie from $235.00 to $230.00 and set a "neutral" rating for the company in a report on Tuesday, January 27th. Evercore reduced their target price on AbbVie from $232.00 to $228.00 and set an "outperform" rating for the company in a report on Wednesday, February 4th. Finally, Wall Street Zen raised AbbVie from a "buy" rating to a "strong-buy" rating in a report on Saturday, February 28th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $253.00.

AbbVie Price Performance

The firm has a market capitalization of $368.16 billion, a PE ratio of 88.23, a P/E/G ratio of 0.76 and a beta of 0.38. The firm has a fifty day moving average price of $220.65 and a 200 day moving average price of $224.11.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie's revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's dividend payout ratio is currently 293.22%.

Insider Activity

In related news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company's stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company's stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On AbbVie

A number of hedge funds and other institutional investors have recently made changes to their positions in ABBV. Brighton Jones LLC raised its stake in shares of AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company's stock valued at $4,072,000 after acquiring an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in shares of AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company's stock valued at $1,294,000 after acquiring an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. raised its stake in shares of AbbVie by 5.0% in the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company's stock valued at $3,056,000 after acquiring an additional 789 shares in the last quarter. Dearborn Partners LLC raised its stake in shares of AbbVie by 1.3% in the 2nd quarter. Dearborn Partners LLC now owns 174,525 shares of the company's stock valued at $32,395,000 after acquiring an additional 2,265 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of AbbVie by 1,266.6% in the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 13,297 shares of the company's stock valued at $2,468,000 after acquiring an additional 12,324 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.